Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients (Q43036643)

12 November 2017

Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients (English)

1 reference

12 November 2017

1 reference

10

Kazuaki Chayama

1 reference

12 November 2017

11

Hiromitsu Kumada

1 reference

12 November 2017

Itaru Ozeki

1

1 reference

12 November 2017

Jun Akaike

2

1 reference

12 November 2017

Yoshiyasu Karino

3

1 reference

12 November 2017

Tomohiro Arakawa

4

1 reference

12 November 2017

Yasuaki Kuwata

5

1 reference

12 November 2017

Takumi Ohmura

6

1 reference

12 November 2017

Takahiro Sato

7

1 reference

12 November 2017

Naohiro Kamiya

8

1 reference

12 November 2017

Ichimaro Yamada

9

1 reference

12 November 2017

Joji Toyota

12

1 reference

12 November 2017

10 May 2011

1 reference

Journal of Gastroenterology

12 November 2017

1 reference

12 November 2017

46

1 reference

12 November 2017

7

1 reference

12 November 2017

929-937

1 reference

Epidemiology of hepatitis C: geographic differences and temporal trends

12 November 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Changing trends in hepatitis C infection over the past 50 years in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Identification of HCV protease inhibitor resistance mutations by selection pressure-based method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Estimating drug efficacy and viral dynamic parameters: HIV and HCV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

A high-throughput SNP typing system for genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0411-0

Genetic heterogeneity of hepatitis C virus.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21556829

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00535-011-0411-0

1 reference

12 November 2017

1 reference